IART Quote, Financials, Valuation and Earnings

Perspective Therapeutics has a net margin of -2.81% compared to Integra Lifesciences Holdings's net margin of --. Integra Lifesciences Holdings's return on equity of -0.42% beat Perspective Therapeutics's return on equity of --.

Integra Lifesciences Holdings has a consensus price target of $27.56, signalling upside risk potential of 19.82%. On the other hand Perspective Therapeutics has an analysts' consensus of $16.15 which suggests that it could grow by 357.51%. Given that Perspective Therapeutics has higher upside potential than Integra Lifesciences Holdings, analysts believe Perspective Therapeutics is more attractive than Integra Lifesciences Holdings.

Integra Lifesciences Holdings has a beta of 1.164, which suggesting that the stock is 16.435% more volatile than S&P 500. In comparison Perspective Therapeutics has a beta of 1.195, suggesting its more volatile than the S&P 500 by 19.546%.

Integra Lifesciences Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Integra Lifesciences Holdings pays -- of its earnings as a dividend. Perspective Therapeutics pays out -- of its earnings as a dividend.

Integra Lifesciences Holdings quarterly revenues are $380.8M, which are larger than Perspective Therapeutics quarterly revenues of --. Integra Lifesciences Holdings's net income of -$10.7M is higher than Perspective Therapeutics's net income of -$15.1M. Notably, Integra Lifesciences Holdings's price-to-earnings ratio is 70.14x while Perspective Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Integra Lifesciences Holdings is 1.07x versus 19.06x for Perspective Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Globus Medical has a net margin of -2.81% compared to Integra Lifesciences Holdings's net margin of 8.28%. Integra Lifesciences Holdings's return on equity of -0.42% beat Globus Medical's return on equity of 2.27%.

Integra Lifesciences Holdings has a consensus price target of $27.56, signalling upside risk potential of 19.82%. On the other hand Globus Medical has an analysts' consensus of $94.77 which suggests that it could grow by 12.92%. Given that Integra Lifesciences Holdings has higher upside potential than Globus Medical, analysts believe Integra Lifesciences Holdings is more attractive than Globus Medical.

Integra Lifesciences Holdings has a beta of 1.164, which suggesting that the stock is 16.435% more volatile than S&P 500. In comparison Globus Medical has a beta of 1.188, suggesting its more volatile than the S&P 500 by 18.849%.

Integra Lifesciences Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Globus Medical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Integra Lifesciences Holdings pays -- of its earnings as a dividend. Globus Medical pays out -- of its earnings as a dividend.

Integra Lifesciences Holdings quarterly revenues are $380.8M, which are smaller than Globus Medical quarterly revenues of $625.7M. Integra Lifesciences Holdings's net income of -$10.7M is lower than Globus Medical's net income of $51.8M. Notably, Integra Lifesciences Holdings's price-to-earnings ratio is 70.14x while Globus Medical's PE ratio is 125.27x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Integra Lifesciences Holdings is 1.07x versus 4.64x for Globus Medical. Usually stocks with elevated PS ratios are considered overvalued.

Haemonetics has a net margin of -2.81% compared to Integra Lifesciences Holdings's net margin of 9.79%. Integra Lifesciences Holdings's return on equity of -0.42% beat Haemonetics's return on equity of 13.51%.

Integra Lifesciences Holdings has a consensus price target of $27.56, signalling upside risk potential of 19.82%. On the other hand Haemonetics has an analysts' consensus of $110.80 which suggests that it could grow by 40.59%. Given that Haemonetics has higher upside potential than Integra Lifesciences Holdings, analysts believe Haemonetics is more attractive than Integra Lifesciences Holdings.

Integra Lifesciences Holdings has a beta of 1.164, which suggesting that the stock is 16.435% more volatile than S&P 500. In comparison Haemonetics has a beta of 0.410, suggesting its less volatile than the S&P 500 by 59.02%.

Integra Lifesciences Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Haemonetics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Integra Lifesciences Holdings pays -- of its earnings as a dividend. Haemonetics pays out -- of its earnings as a dividend.

Integra Lifesciences Holdings quarterly revenues are $380.8M, which are larger than Haemonetics quarterly revenues of $345.5M. Integra Lifesciences Holdings's net income of -$10.7M is lower than Haemonetics's net income of $33.8M. Notably, Integra Lifesciences Holdings's price-to-earnings ratio is 70.14x while Haemonetics's PE ratio is 32.70x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Integra Lifesciences Holdings is 1.07x versus 2.98x for Haemonetics. Usually stocks with elevated PS ratios are considered overvalued.

ResMed has a net margin of -2.81% compared to Integra Lifesciences Holdings's net margin of 25.43%. Integra Lifesciences Holdings's return on equity of -0.42% beat ResMed's return on equity of 23.76%.

Integra Lifesciences Holdings has a consensus price target of $27.56, signalling upside risk potential of 19.82%. On the other hand ResMed has an analysts' consensus of -- which suggests that it could grow by 9.04%. Given that Integra Lifesciences Holdings has higher upside potential than ResMed, analysts believe Integra Lifesciences Holdings is more attractive than ResMed.

Integra Lifesciences Holdings has a beta of 1.164, which suggesting that the stock is 16.435% more volatile than S&P 500. In comparison ResMed has a beta of 0.698, suggesting its less volatile than the S&P 500 by 30.155%.

Integra Lifesciences Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ResMed offers a yield of 0.86% to investors and pays a quarterly dividend of $0.53 per share. Integra Lifesciences Holdings pays -- of its earnings as a dividend. ResMed pays out 27.65% of its earnings as a dividend. ResMed's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Integra Lifesciences Holdings quarterly revenues are $380.8M, which are smaller than ResMed quarterly revenues of $1.2B. Integra Lifesciences Holdings's net income of -$10.7M is lower than ResMed's net income of $311.4M. Notably, Integra Lifesciences Holdings's price-to-earnings ratio is 70.14x while ResMed's PE ratio is 31.14x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Integra Lifesciences Holdings is 1.07x versus 7.21x for ResMed. Usually stocks with elevated PS ratios are considered overvalued.